Abstract
Bacteria use multiple strategies to bypass the inflammatory responses in order to survive in the host cells. In this review, we discuss the mechanism of the bacerial proteins in inhibiting inflammation. We highlight the antiinflammatory roles of the type three secretion proteins including Salmonella AvrA, Enteropathogenic Escherichia coli Cif, and Yersinia YopJ, Staphylococcus aureus extracellular adherence protein, and Chlamydia proteins. We also discuss the research progress on the structures of these anti-inflammatory bacterial proteins. The current therapeutic methods for diseases, such as inflammatory bowel diseases, sclerosis, lack influence on the course of chronic inflammation and infection. Therefore, based on the molecular mechanism of the anti-inflammatory bacterial proteins and their 3-Dimension structure, we can design new peptides or non-peptidic molecules that serve as anti-inflammatory drugs without the possible side effect of promoting bacterial infection.
Keywords: Bacteria, type three secretion system, effector, bacterial-tail-specific protease, inflammation, anti-inflammation, acetylation, ubiquitination, phosphorylation, intestine
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Pathogenic Bacterial Proteins and their Anti-Inflammatory Effects in the Eukaryotic Host
Volume: 8 Issue: 3
Author(s): Jun Sun
Affiliation:
Keywords: Bacteria, type three secretion system, effector, bacterial-tail-specific protease, inflammation, anti-inflammation, acetylation, ubiquitination, phosphorylation, intestine
Abstract: Bacteria use multiple strategies to bypass the inflammatory responses in order to survive in the host cells. In this review, we discuss the mechanism of the bacerial proteins in inhibiting inflammation. We highlight the antiinflammatory roles of the type three secretion proteins including Salmonella AvrA, Enteropathogenic Escherichia coli Cif, and Yersinia YopJ, Staphylococcus aureus extracellular adherence protein, and Chlamydia proteins. We also discuss the research progress on the structures of these anti-inflammatory bacterial proteins. The current therapeutic methods for diseases, such as inflammatory bowel diseases, sclerosis, lack influence on the course of chronic inflammation and infection. Therefore, based on the molecular mechanism of the anti-inflammatory bacterial proteins and their 3-Dimension structure, we can design new peptides or non-peptidic molecules that serve as anti-inflammatory drugs without the possible side effect of promoting bacterial infection.
Export Options
About this article
Cite this article as:
Sun Jun, Pathogenic Bacterial Proteins and their Anti-Inflammatory Effects in the Eukaryotic Host, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2009; 8 (3) . https://dx.doi.org/10.2174/187152309789151986
DOI https://dx.doi.org/10.2174/187152309789151986 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Review of Airway Illnesses by Kytococcus and Rothia and a Look at Inhalatory Vancomycin as a Treatment Support
Recent Patents on Anti-Infective Drug Discovery Prediction Models and Scores in Adult Congenital Heart Disease
Current Pharmaceutical Design Evaluation of Echocardiographic Abnormalities in HIV Positive Patients Treated with Antiretroviral Medications
Infectious Disorders - Drug Targets Heart Failure in South America
Current Cardiology Reviews Role of Old Antibiotics in Multidrug Resistant Bacterial Infections
Current Drug Targets Community-Acquired Pneumonia in Children
Recent Patents on Inflammation & Allergy Drug Discovery Continuous Infusion of Antibiotics in Critically Ill Patients
Current Clinical Pharmacology Echocardiographic Hemodynamic Monitoring in the Critically Ill Patient
Current Cardiology Reviews Chemical Countermeasures for the Control of Bacterial Biofilms: Effective Compounds and Promising Targets
Current Medicinal Chemistry Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem
Current Cardiology Reviews Sphingomonas Paucimobilis Bacteremia in a Patient with Major Burns Injury: A Case Report
New Emirates Medical Journal Hallmarks in the Therapeutic Approach of Aortic Aneurysms: The Main Contributors
Current Pharmaceutical Design Role of Molecular Analysis After Autopsy Negative Sudden Death in the Young
Current Pediatric Reviews Brucella as a Potential Agent of Bioterrorism
Recent Patents on Anti-Infective Drug Discovery Microbial Biofilms: Impact on the Pathogenesis of Periodontitis, Cystic Fibrosis, Chronic Wounds and Medical Device-Related Infections
Current Topics in Medicinal Chemistry Current Developments in Therapeutic and Diagnostic Strategies for Q Fever: Glimpses of Patent Analysis
Recent Patents on Anti-Infective Drug Discovery Acethylcholinesterase Inhibition, Antibacterial and Antioxidant Properties of Diaryl Oxalates
Current Enzyme Inhibition Bacterial Adaptation and Infection
Inflammation & Allergy - Drug Targets (Discontinued) New Treatments for Emerging Cystic Fibrosis Pathogens other than Pseudomonas
Current Pharmaceutical Design Brucella Pneumonia with Systemic Complications and Pancytopenia: A Case Report
Infectious Disorders - Drug Targets